Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.
Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such as Eczema Area and Severity Index (EASI)-75/90, Investigator Global Assessment (IGA), and itch scores alongside patient-reported outcomes to guide decisions while also considering disease severity and the impact of atopic comorbidities in treatment approaches.
Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the severity of the current respiratory virus season and stresses the importance of vaccinations to protect against influenza, COVID-19, RSV, and more.
Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN underscores how critical simple, but factual, conversations can be with parents when it comes to pediatric care.
Panelists discuss the diagnosis and referral process for patients with pediatric atopic dermatitis (AD) from both the dermatologist and allergy perspectives, including when a child should be referred to a dermatologist and the importance of a multidisciplinary approach to care for optimizing AD management, with insights on the roles each team member plays in patient care.
Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.
Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.
Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to other allergic diseases such as food allergies, asthma, and allergic rhinitis, including early indicators that may predict future comorbidities.
Based on recent reports, norovirus outbreaks in the 2024-2025 seasonal year is above the range reported from the 2012-2020 and 2021-2024 seasonal years.
Robert Frenck, MD, offers several practical tips to use when discussing pediatric vaccination among vaccine-hesitant parents.
Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial, and explains the role the pediatrician can play in care and recruitment.
Susan Carnell, PhD, highlights the nuanced relationship between social media use and binge eating in adolescents, noting the importance of addressing addictive behaviors and seeking support when needed.
Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH.
Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.
Robert Frenck, MD, explained why 2024 was a big step in the right direction for RSV prevention, and emphasized the importance of vaccination against preventable diseases.
Susan Carnell, PhD explains social media addiction symptoms, but not time on social media, were cross-sectionally and prospectively associated with binge eating.
Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.
Contemporary Pediatrics' editorial advisory member Russell Libby, MD, FAAP, highlights 2024 FDA approval of epinephrine nasal spray (Neffy) in this video interview.
Greg Forlenza, MD, highlights data from the CLVer trial that included advanced diabetes technology in newly diagnosed T1D patients.
"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."
Nathan Kuppermann, MD, MPH, explains the different quartiles of the pediatric emergency department readiness scale, and why the top tier is so crucial for pediatric patients.
This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.
Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.
A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.
In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.
In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.
Paul Kruszka, MD, MPH, FACMG, explains for general providers the difference between screening and diagnosis regarding whole genome sequencing and how it could play a role in the primary care setting.
